Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-002344-23
    Sponsor's Protocol Code Number:2020/490
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2020-06-10
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2020-002344-23
    A.3Full title of the trial
    Regorafenib in combination with metronomic cyclophosphamide, capecitabine, and low-dose aspirin in metastatic colorectal cancer carcinoma
    An open-label phase II
    Régorafenib en association avec une polychimiothérapie métronomique à base de cyclophosphamide, capecitabine et aspirine à faible dose dans le traitement des cancers colorectaux métastatiques. Etude de phase II
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Regorafenib in combination with metronomic cyclophosphamide, capecitabine, and low-dose aspirin in metastatic colorectal cancer carcinoma
    An open-label phase II
    Régorafenib en association avec une polychimiothérapie métronomique à base de cyclophosphamide, capecitabine et aspirine à faible dose dans le traitement des cancers colorectaux métastatiques. Etude de phase II
    A.3.2Name or abbreviated title of the trial where available
    REPROGRAM-01
    REPROGRAM-01
    A.4.1Sponsor's protocol code number2020/490
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorCHU de Besançon
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBAYER
    B.4.2CountryFrance
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisation
    B.5.2Functional name of contact point
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name STIVARGA
    D.2.1.1.2Name of the Marketing Authorisation holderBAYER AG
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRégorafenib
    D.3.4Pharmaceutical form Coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.1CAS number 755037-03-7
    D.3.9.3Other descriptive nameREGORAFENIB
    D.3.9.4EV Substance CodeSUB73090
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number160
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Cyclophosphamide métronomique
    D.2.1.1.2Name of the Marketing Authorisation holderBAXTER SAS
    D.2.1.2Country which granted the Marketing AuthorisationFrance
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCyclophosphamide métronomique
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCYCLOPHOSPHAMIDE
    D.3.9.1CAS number 50-18-0
    D.3.9.4EV Substance CodeSUB06859MIG
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Xeloda
    D.2.1.1.2Name of the Marketing Authorisation holderROCHE registration GmbH
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCapécitabine
    D.3.4Pharmaceutical form Coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.9.3Other descriptive nameCAPECITABINE
    D.3.9.4EV Substance CodeSUB12474MIG
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Kardégic
    D.2.1.1.2Name of the Marketing Authorisation holderSanofi Aventis France
    D.2.1.2Country which granted the Marketing AuthorisationFrance
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAspirine
    D.3.4Pharmaceutical form Powder for oral solution
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Metastatic colorectal cancer
    Cancer colorectal métastatique
    E.1.1.1Medical condition in easily understood language
    Metastatic colorectal cancer
    Cancer colorectal métastatique
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The main objective of this clinical trial is to assess the potential clinical interest of regorafenib in combination of metronomic chemotherapies and low-dose aspirin in patients with metastatic colorectal cancer carcinoma, previously exposed or not considered as candidate for 5FU, CPT11, oxaliplatin, anti-VEGF and anti-EGFR, by evaluation of the objective response rate (ORR) during treatment period
    Evaluation du taux de réponse objective durant le traitement chez des patients traités par une polychimiothérapie métronomique à base de capecitabine et cyclophosphamide, aspirine à faible dose et régorafenib, en 3ème ou 4ème ligne de chimiothérapie pour un adénocarcinome colorectal métastatique
    E.2.2Secondary objectives of the trial
    1. To investigate the impact of regorafenib and metronomic chemotherapy on overall survival (OS)
    2. To investigate the impact of regorafenib and metronomic chemotherapy on progression-free survival (PFS)
    3. To investigate the impact of combined treatment on patient’s health related quality of life (QoL)
    4. To evaluate the safety of regorafenib in association with metronomic chemotherapies
    5. To correlate CHUN morphologic criteria with RECIST v1.1 response
    - Etudier l’impact de l’association du régorafenib à une polychimiothérapie métronomique et aspirine à faible dose sur la survie globale
    - Etudier l’impact de l’association du régorafenib à une polychimiothérapie métronomique et aspirine à faible dose sur la survie sans progression
    - Etudier l’impact de la combinaison de traitement sur la qualité de vie relative à la santé
    - Evaluer la tolérance du régorafenib en association avec une polychimiothérapie métronomique et aspirine à faible dose
    - Corréler les critères morphologiques CHUN avec la réponse selon les critères RECIST v1.1
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    1. To analyse CD3, CD8, FOXP3 expression
    2. To characterize the impact of the combination on anti-tumor response and on the myelosuppression
    3. To evaluate telomerase/CoA/mesothelin-specific T cell response before and after treatment in peripheral blood mononuclear cells
    4. To evaluate the effect of tumor microenvironment targeting on the evolution of the stromal-specific serum signature
    5. To characterize the predictive value of soluble biomarkers
    L'étude ancillaire sera réalisée sur des collections d'échantillons biologiques. Les objectifs sont les suivants:
    - Analyser l'expression de CD3, CD8, FOXP3
    - Caractériser l'impact de l'association sur la réponse anti-tumorale et sur la myélosuppression
    - Évaluer la réponse des lymphocytes T spécifiques à la télomérase / CoA / mésothéline avant et après le traitement dans les cellules mononucléaires du sang périphérique (PBMC)
    - Évaluer l'effet du ciblage du microenvironnement tumoral sur l'évolution de la signature sérique stromale
    - Caractériser la valeur prédictive des biomarqueurs solubles
    E.3Principal inclusion criteria
    1. Patients with histologically proven metastatic colorectal cancer in progression after previous standard treatments (5FU, CPT11, oxaliplatin, anti-VEGF and anti-EGFR therapy if KRAS and NRAS WT), or not considered as candidate for these treatments
    2. Life expectancy of at least 3 months
    3. Female or male with age >18 years old
    4. Performance status = 0 or 1 (Annex 1)
    5. Measurable disease defined according to RECIST v1.1 guidelines (scanner or MRI) (Annex 2)
    6. Adequate bone marrow, liver and renal functions.
    a. Haemoglobin ≥ 9 g/dL; absolute neutrophil count (ANC) ≥ 1.5 x 109/L; platelets ≥ 100 x 109/L
    b. Total serum bilirubin ≤ 1.5 times upper normal value (ULN), serum alkaline phosphatase < 5 times ULN, aminotransferases (AST/ALT) ≤ 3 × ULN in absence of hepatic metastasis or ≤ 5 if presence of hepatic lesions
    c. Cockcroft glomerular filtration rate > 50 ml/min
    d. Proteinuria <2+ (dipstick urinalysis) or ≤1g/24hour
    7. Imaging target greater than one cm must be visible on CT,
    8. No contraindication to Iodine contrast media injection during CT
    9. For female patients of childbearing potential, negative pregnancy test within 14 days before starting the study drug. Men and women are required to use adequate birth control during the study (when applicable),
    10. Signed and dated informed consent,
    11. Ability to comply with the study protocol, in the Investigator’s judgment.
    12. Registration in a national health care system (CMU included).
    1. Patients atteints d'un cancer colorectal métastatique histologiquement prouvé en progression après traitements standards (5-FU, CPT11, oxaliplatine, anti-VEGF et anti-EGFR si KRAS et NRAS WT), ou non candidats pour ces traitements,
    2. Espérance de vie d’au moins 3 mois,
    3. Homme ou femme ≥ 18 ans,
    4. Performance statut ECOG à 0 ou 1,
    5. Maladie mesurable définie selon les critères RECIST v1.1 (scanner ou IRM),
    6. Fonctions biologiques, hématologiques, rénales et hépatiques adéquates :
    o Hémoglobine ≥ 9 g/dl; PNN ≥ 1,5 x 109/l; plaquettes ≥ 100 x 109/l,
    o Bilirubine sérique totale ≤ 1,5 fois la valeur normale supérieure (ULN ; upper normal value), phosphatase alcaline sérique <5 fois ULN, transaminases (AST / ALT) ≤ 3 × ULN en d'absence de métastases hépatiques ou ≤ 5 en cas de présence de lésions hépatiques,
    o Débit de filtration glomérulaire Cockcroft > 50 ml/min,
    o Protéinurie <2+ (bandelette urinaire) ou ≤1g/24 heures,
    7. La lésion cible (supérieure à un cm) doit être visible sur le scanner,
    8. Aucune contre-indication à l'injection de produit de contraste d'iode,
    9. Pour les patientes en âge de procréer, test de grossesse négatif dans les 14 jours avant de commencer les médicaments à l'étude. Les hommes et les femmes doivent utiliser un contraceptif adéquat pendant la durée de l'étude (le cas échéant),
    10. Consentement éclairé daté et signé,
    11. Capacité de se conformer au protocole de l’étude, selon le jugement de l’investigateur,
    12. Couvert par l’assurance maladie (CMU inclus).
    E.4Principal exclusion criteria
    Non-eligible to a clinical trial:
    1. Diagnosis of additional malignancy within 2 years prior to the inclusion (exception of curatively treated basal cell carcinoma of the skin and/or curatively resected in situ cervical cancer),
    2. Current participation in a study of an investigational agent or in the period of exclusion
    3. Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before inclusion in the trial ;
    4. Patient under judicial protection (curatorship, tutorship) and/or deprived of freedom,
    Cancer-specific or treatment-specific exclusion criteria:
    5. Planned surgical procedure within the first month of treatment or any procedure that might change the timing of regorafenib administration during the first month of treatment,
    6. Previous exposition to regorafenib
    7. Previous exposition to other anti-angiogenic treatment than bevacizumab and aflibercept
    8. Complete deficit in dihydropyrimidine deshydrogenase (DPD),
    9. Major surgical procedure, open biopsy or significant traumatic injury within 28 days before start of study medication,
    10. Pregnant or breast-feeding subjects,
    11. Congestive Heart Failure ≥ New York Heart Association (NYHA) class 2, unstable angina (anginal symptomatology at rest),
    12. Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months),
    13. Myocardal infarction less than 6 months before start of study drug,
    14. Cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or digoxin are permitted),
    15. Uncontrolled hypertension (Systolic blood pressure >150 mmHg and/or diastolic pressure >100 mmHg despite optimal medical management), or history of hypertensive crisis, or hypertensive encephalopathy
    16. Pleural effusion or ascites that causes respiratory compromise (≥ CTCAE grade 2 dyspnea),
    17. Ongoing infection >grade 2 CTCAE V5,
    18. Known History of human immunodeficiency virus (HIV) infection,
    19. Active hepatitis B or C or chronic hepatitis B or C requiring treatment with antiviral therapy,
    20. Subjects with seizure disorder requiring medication,
    21. History of organ allograft,
    22. Subjects with evidence or history of any bleeding diathesis, irrespective of severity,
    23. Any haemorrhage or bleeding event ≥ CTCAE Grade 3 within 4 weeks prior to the start of study medication,
    24. Serious, Non-healing wound, active ulcer or untreated bone fracture,
    25. History of abdominal fistula, GI perforation, intra-abdominal abscess or active GI bleeding within 6 months prior to inclusion,
    26. Dehydration CTCAE v4 grade ≥1,
    27. Known hypersensitivity to any of the study drugs, study drug classes or excipient in the formulation,
    28. Interstitial lung disease with ongoing signs or symptoms,
    29. Persistent proteinuria of CTCAE Grade 3 (>3.5 g/24 hours),
    30. Subject unable to swallow oral medications,
    31. Any malabsorption condition, unresolved toxicity higher than CTCAE (V4) Grade 1 attributed to any prior therapy/procedure excluding alopecia, hypothyroidism and oxaliplatin induced neuropathy ≤ Grade 2,
    32. Systemic anticancer therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy, and hormonal therapy during this trial or within 3 weeks,
    33. Treatment with any other investigational medicinal product within 28 days prior to study entry, EXCEPT for ASPIRIN,
    34. Chronic treatment with drug potentially interacting with regorafenib i.e. CYP3A4 or UGT1A9 inductor/inhibitor.
    1. Antécédents de cancer dans les deux années précédant l’inclusion (à l'exception de carcinome basocellulaire traité de façon curatrice et/ou de cancer du col de l’utérus réséqué de façon curatrice),
    2. Sujets inclus dans une autre étude interventionnelle avec produit de santé ou étant dans la période d’exclusion d’une autre étude,
    3. Maladie psychiatrique compromettant la compréhension de l’information ou la réalisation de l’étude,
    4. Personnes vulnérables selon la loi (mineurs, majeurs sous protection, personnes privées de liberté...)
    5. Chirurgie programmée dans le premier mois de traitement ou toute procédure pouvant modifier les modalités de prises du régorafenib pendant le premier mois de traitement,
    6. Exposition antérieure au régorafénib,
    7. Exposition précédente à des traitements anti-angiogéniques autres que bevacizumab et aflibercept,
    8. Déficit complet en dihydropyrimidine deshydrogenase (DPD),
    9. Chirurgie majeure, biopsie chirurgicale ou blessure dans les 28 jours précédant le début de la prise médicamenteuse dans le cadre du protocole,
    10. Femmes enceintes, susceptibles de l’être ou en cours d’allaitement,
    11. Insuffisance cardiaque ≥ 2 selon le score du New York Heart Association (NYHA), angor instable (symptomatologie angineuse au repos), ou angor d'apparition récente (apparition dans les 3 mois précédent l’inclusion),
    12. Infarctus du myocarde datant de moins de 6 mois avant l’inclusion,
    13. Arythmie cardiaque demandant un traitement spécifique (l’utilisation des béta-bloquant et de la digoxine est autorisée)
    14. Hypertension non contrôlée : Pression artérielle systolique (PAS) >150 mmHg et/ou Pression artérielle diastolique (PAD) >100 mmHg malgré un traitement adéquat optimal) ou antécédents de crise hypertensive, ou d'encéphalopathie hypertensive,
    15. Épanchement pleural ou ascite entraînant une altération respiratoire (dyspnée CTCAE ≥grade 2),
    16. Infection active >grade 2 CTCAE V5,
    17. Infection connue et virus du VIH
    18. Hépatite B ou C active ; ou hépatite B ou C chronique nécessitant un traitement par thérapie anti virale,
    19. Sujets souffrant de troubles convulsifs nécessitant des médicaments,
    20. Histoire d’allogreffe d'organe,
    21. Sujets présentant des preuves ou des antécédents de coagulopathie hémorragique, quelle que soit leur gravité,
    22. Toute hémorragie ou hémorragie ≥ CTCAE grade 3 dans les 4 semaines précédant le début des médicaments à l'étude,
    23. Plaie grave, non cicatrisante, ulcère actif ou fracture osseuse non traitée,
    24. Antécédents de fistule abdominale, de perforation gastro-intestinale, d'abcès intra-abdominal ou de saignement gastro-intestinal actif dans les 6 mois précédant l’inclusion,
    25. Déshydratation CTCAE v4 grade ≥1,
    26. Hypersensibilité connue à l’une des molécules à l'étude, aux classes de médicaments à l'étude ou à un excipient dans la formulation,
    27. Maladie pulmonaire interstitielle avec signes ou symptômes persistants,
    28. Protéinurie persistante : CTCAE Grade 3 (>3,5 g/24 heures),
    29. Sujet incapable d'avaler des médicaments oraux,
    30. Tout état de malabsorption, toxicité non résolue supérieure à CTCAE (V4) Grade 1 attribuée à toute thérapie/procédure antérieure excluant l'alopécie, l'hypothyroïdie et la neuropathie induite par l'oxaliplatine ≤ Grade 2,
    31. Traitement systémique anti-cancéreux incluant toute chimiothérapie cytotoxique, immunothérapie, thérapie ciblée, ou traitement hormonal pendant l’étude ou dans les trois dernières semaines,
    32. Traitement à base de l’une des molécules à l’essai dans les 28 jours précédents l’entrée dans l’étude SAUF POUR L’ASPIRINE
    33. Co-administration de médicaments susceptibles d’interagir avec le régorafenib c'est-à-dire les inducteurs / inhibiteurs du CYP3A4 ou de l'UGT1A9.
    E.5 End points
    E.5.1Primary end point(s)
    The objective response rate (ORR) will be defined by RECIST v1.1 criteria (Annex 2) as the best disease response observed during the treatment period. ORR rate is defined as the proportion of patients whose tumor regresses or does not progress under treatment.
    Le taux de réponse objective sera défini selon les critères RECIST v1.1, comme la meilleure réponse tumorale observée durant la période de traitement. Le taux de réponse objective est défini par l’addition des taux de réponses complètes et de réponses partielles.
    E.5.1.1Timepoint(s) of evaluation of this end point
    during the treatment period.
    durant la période de traitement
    E.5.2Secondary end point(s)
    1. Overall survival (OS): defined as the time from the treatment start date to death from any cause
    2. Progression-free survival (PFS): defined as the time from the treatment start date to disease progression or death from any cause
    3. Health related Quality of life :
    o EORTC QLC30 + CR29, EQ-5D-3L questionnaires (Annex 3, 4, 5)
    o TUDD (Time Until Definitive Deterioration) of 5 targeted dimensions : Global health/ Pain/ Physical Functioning/ Fatigue / Emotional Functioning
    o Number and volumes of paracentesis and drainages (ascite or pleural effusions)
    o Number of days of hospitalization
    o Number of days taking level 3 analgesics
    4. Toxicities graded according to NCI-CTCAE criteria version 5 (Annex 6)
    5. Evaluation of CHUN morphological criteria and correlation with response according to RECIST v1.1 and serum stromal biomarkers (Annex 7).
    1. Survie globale (OS): définie comme le temps écoulé entre la date de début du traitement et le décès quelle qu'en soit la cause
    2. Survie sans progression (PFS): définie comme le temps entre la date de début du traitement et la progression de la maladie ou le décès quelle qu'en soit la cause
    3. Qualité de vie liée à la santé:
    o EORTC QLC30 + CR29, questionnaires EQ-5D-3L (annexes 3, 4, 5)
    o TUDD (temps jusqu'à la détérioration définitive) de 5 dimensions ciblées: Santé globale / Douleur / Fonctionnement physique / Fatigue / Fonctionnement émotionnel
    o Nombre et volumes de paracentèse et de drainage (ascite ou épanchements pleuraux)
    o Nombre de jours d'hospitalisation
    o Nombre de jours de prise d'analgésiques de niveau 3
    4. Toxicités classées selon les critères NCI-CTCAE version 5 (annexe 6)
    5. Évaluation des critères morphologiques CHUN et corrélation avec la réponse selon RECIST v1.1 et les biomarqueurs stromaux sériques (annexe 7).

    E.5.2.1Timepoint(s) of evaluation of this end point
    date to death
    date du décès
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety No
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned2
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 30
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 19
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state49
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Non
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-08-19
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-06-16
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 21:11:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA